1. Home
  2. GRI vs SOBR Comparison

GRI vs SOBR Comparison

Compare GRI & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.37

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo SOBR Safe Inc.

SOBR

SOBR Safe Inc.

HOLD

Current Price

$0.54

Market Cap

3.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
SOBR
Founded
2018
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.3M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
GRI
SOBR
Price
$2.37
$0.54
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$160.00
N/A
AVG Volume (30 Days)
31.4K
147.5K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
72.19
EPS
N/A
N/A
Revenue
N/A
$212,736.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.25
52 Week Low
$0.18
$0.48
52 Week High
$6.70
$5.80

Technical Indicators

Market Signals
Indicator
GRI
SOBR
Relative Strength Index (RSI) 46.45 34.65
Support Level $2.16 N/A
Resistance Level $2.66 $1.03
Average True Range (ATR) 0.19 0.09
MACD -0.03 -0.02
Stochastic Oscillator 30.71 16.32

Price Performance

Historical Comparison
GRI
SOBR

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

Share on Social Networks: